Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

NeoVaxSyn Inc
Profile last edited on: 10/6/2021      CAGE: 7RK00      UEI: EHMTBALCKFE8

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2012
First Award
2020
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4140 Cochrane Parkway
Ames, IA 50014
   (515) 708-5831
   N/A
   N/A
Location: Single
Congr. District: 04
County: Story

Public Profile

Involving various personnel with University of Iowa association and what is whatis called the ISU Start-Up Factory, NeoVaxSyn Inc is structured around developing immunogens and optimizing vaccine technologies that can enable the body’s immune system better to target critical epitopes on viral surface antigens.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,197,311
Phase II Dollars
$0
Total Awarded
$1,197,311

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $597,312
Project Title: Induction of bnAbs against HIV-1 gp41.
2022 1 NIH $300,000
Project Title: Preclinical evaluation of HIV-1 envelope immunogens in humanized mice
2021 1 NIH $300,000
Project Title: The Contractor Shall Utilize Nanoparticles to Deliver the Mper-Based Immunogens to Elicit Bnabs Against the MPER of HIV-1 gp41 to Develop a Protective
2020 1 NIH $299,999
Project Title: The Objective of This Contract Is to Utilize Gold Nanoparticles (GNP) to Elicit Broadly Neutralizing Antibodies (bnAbs) Against the Fusion Peptide (FP)

Key People / Management

  Michael Cho -- Founder

  Nicole Cho -- Administrative Assistant

  Chowda Rekalakunta-Venkataravappa

  Vikram Srivastava

  Chowda Venkataravappa

Company News

There are no news available.